← Eichor
Condition: Skin Diseases Parasitic Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Skin Diseases Parasitic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis
Phase 2 · 1 location(s) · Hayder Adnan Fawzi · NCT06798415OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Phase N/A · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT06514560Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical
Phase 4 · 1 location(s) · Kirby Institute · NCT07145736Clinical Prognostic Score to Predict Relapse in VL
Phase N/A · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT05602610Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
NA · 1 location(s) · IRCCS Sacro Cuore Don Calabria di Negrar · NCT06307171Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
NA · 1 location(s) · Bioaster · NCT06350851A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Phase 2/Phase 3 · 2 location(s) · Programme National de Lutte contre l'Onchocercose, Republic · NCT06252961Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Paki
Phase 3 · 2 location(s) · Medecins Sans Frontieres, Netherlands · NCT04268524Diagnosis and Treatment of Leishmania Infections
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00344188LEISH-PED: Study on Leishmaniasis in Children
Phase N/A · 1 location(s) · Meyer Children's Hospital IRCCS · NCT07504757Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
NA · 1 location(s) · Uwemedimo Friday Ekpo · NCT07707817Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine
Phase 2 · 1 location(s) · Fundacion Nacional de Dermatologia · NCT06550609Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)
Phase N/A · 5 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06793111Sensitivity of Self-collected Skin Sampling for Scabies: a Pilot Study
EARLY_Phase 1 · 1 location(s) · Radboud University Medical Center · NCT06546579Host Response to Infection and Treatment in Filarial Diseases
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00001230Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).
NA · 1 location(s) · Oystershell NV · NCT07660354Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup
NA · 1 location(s) · Armauer Hansen Research Institute, Ethiopia · NCT06746350Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.
Phase 3 · 1 location(s) · Universidad de Antioquia · NCT06822478Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
Phase 2 · 1 location(s) · Hayder Adnan Fawzi · NCT06797544Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate
Phase 2 · 1 location(s) · Al-Mustafa University College · NCT06798402
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.